1123515-40-1 Usage
Description
N1-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-yl)-4-methylbenzene-1,3-diamine is a synthetic organic molecule with the molecular formula C19H17F2N5O. It belongs to the class of benzene diamines and is characterized by its unique chemical structure, which includes a pyrimidinyl group and a difluoromethoxyphenyl group. N1-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-yl)-4-methylbenzene-1,3-diamine has potential as an enzyme inhibitor and has been studied for its therapeutic applications in treating various diseases, such as cancer and inflammatory conditions.
Uses
Used in Pharmaceutical Industry:
N1-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-yl)-4-methylbenzene-1,3-diamine is used as a potential enzyme inhibitor for the development of targeted drugs. Its unique chemical structure allows for specific interactions with certain enzymes, making it a promising candidate for the treatment of various diseases, including cancer and inflammatory conditions.
Used in Research and Development:
N1-(5-(4-(difluoromethoxy)phenyl)pyrimidin-2-yl)-4-methylbenzene-1,3-diamine is utilized in research and development for the study of its potential therapeutic applications. Its chemical properties and interactions with enzymes make it a valuable compound for further investigation and exploration of its potential uses in medicine.
Check Digit Verification of cas no
The CAS Registry Mumber 1123515-40-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,2,3,5,1 and 5 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1123515-40:
(9*1)+(8*1)+(7*2)+(6*3)+(5*5)+(4*1)+(3*5)+(2*4)+(1*0)=101
101 % 10 = 1
So 1123515-40-1 is a valid CAS Registry Number.
1123515-40-1Relevant articles and documents
5- (4- (HALOALKOXY) PHENYL) PYRIMIDINE-2-AMINE COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
-
Page/Page column 55-56, (2009/04/25)
The invention provides compounds of formula (1) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit, PDGFRα, PDGFRβ, CSF1R, AbI, BCR-AbI, CSK, JNK1, JNK2, p38, p70S6K, TGFβ, SRC, EGFR, trkB, FGFR3. Fes, Lck, Syk, RAF, MKK4, MKK6, SAPK2β, BRK, Fms, KDR, c-rapor b-raf kinases.
